Minimizing the Inhibitory Effect of Neutralizing Antibody for Efficient Gene Expression in the Liver With Adeno-associated Virus 8 Vectors
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Neutralizing antibodies (NAbs) against adeno-associated viruses (AAVs) are known to interfere with AAV vector-mediated gene transfer by intravascular delivery. Evading the inhibitory effects of antibodies against AAV vectors is necessary for efficient transfer of therapeutic genes clinically. For this purpose, we tested the efficacy of saline flushing in order to avoid contact of vectors with NAbs present in blood. Direct injection of the AAV8 vector carrying the factor IX (FIX) gene into the portal vein of macaques using saline flushing achieved transgene-derived FIX expression (4.7 ± 2.10-10.1 ± 5.45% of normal human FIX concentration) in the presence of NAbs. Expression was as efficient as that (5.43 ± 2.59-12.68 ± 4.83%) in macaques lacking NAbs. We next tested the efficacy of saline flushing using less invasive balloon catheter-guided injection. This approach also resulted in efficient expression of transgene-derived FIX (2.5 ± 1.06-9.0 ± 2.37%) in the presence of NAbs (14-56× dilutions). NAbs at this range of titers reduced the efficiency of transduction in the macaque liver by 100-fold when the same vector was injected into mesenteric veins without balloon catheters. Our results suggest that portal vein-directed vector delivery strategies with flushing to remove blood are efficacious for minimizing the inhibitory effect of anti-AAV antibodies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
The hemophilias--from royal genes to gene therapy
Mannucci, P. M., & Tuddenham, E. G. D. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106073442307 · Cited by 1,110
Boutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970
AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
Manno, C. S., Chew, A. J., Hutchison, S., Larson, P. J., Herzog, R. W., Arruda, V. R., Tai, S. J., Ragni, M. V., Thompson, A., Ozelo, M., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3296 · Cited by 749
Adeno-Associated Virus Antibody Profiles in Newborns, Children, and Adolescents
Calcedo, R., Morizono, H., Wang, L., McCarter, R., He, J., Jones, D., Batshaw, M. L., & Wilson, J. M. (2011) · Clinical and Vaccine Immunology · doi:10.1128/cvi.05107-11 · Cited by 345
Nathwani, A. C., Rosales, C., McIntosh, J., Rastegarlari, G., Nathwani, D., Raj, D., Nawathe, S., Waddington, S. N., Bronson, R., Jackson, S., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.274 · Cited by 345
Immune Responses to AAV in Clinical Trials
Mingozzi, F., & A. High, K. (2011) · Current Gene Therapy · doi:10.2174/156652311796150354 · Cited by 324
Moskalenko, M., Chen, L., van Roey, M., Donahue, B. A., Snyder, R. O., McArthur, J. G., & Patel, S. D. (2000) · Journal of Virology · doi:10.1128/jvi.74.4.1761-1766.2000 · Cited by 253
Enhancing the Clinical Potential of AAV Vectors by Capsid Engineering to Evade Pre-Existing Immunity
Bartel, M. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00204 · Cited by 108
Research works printed but not linked: 25
- Pasi, 2001, Gene therapy for haemophilia, Br J Haematol, 115, 744, 10.1046/j.1365-2141.2001.03225.x · DOI
- VandenDriessche, 2003, Gene therapy for the hemophilias, J Thromb Haemost, 1, 1550, 10.1046/j.1538-7836.2003.00265.x · DOI
- Chuah, 2004, Preclinical and clinical gene therapy for haemophilia, Haemophilia, 10, 119, 10.1111/j.1365-2516.2004.00984.x · DOI
- Chuah, 2004, Clinical gene transfer studies for hemophilia A, Semin Thromb Hemost, 30, 249, 10.1055/s-2004-825638 · DOI · Paper page
- Hasbrouck, 2008, AAV-mediated gene transfer for the treatment of hemophilia B: problems and prospects, Gene Ther, 15, 870, 10.1038/gt.2008.71 · DOI
- Kay, 2000, Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector, Nat Genet, 24, 257, 10.1038/73464 · DOI · Paper page
- Jiang, 2006, Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B, Mol Ther, 14, 452, 10.1016/j.ymthe.2006.05.004 · DOI · Paper page
- Nathwani, 2002, Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques, Blood, 100, 1662, 10.1182/blood-2002-02-0589 · DOI · Paper page
- Nathwani, 2006, Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver, Blood, 107, 2653, 10.1182/blood-2005-10-4035 · DOI · Paper page
- Nathwani, 2007, Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates, Blood, 109, 1414, 10.1182/blood-2006-03-010181 · DOI · Paper page
- Ishiwata, 2010, Mutant macaque factor IX T262A: a tool for hemophilia B gene therapy studies in macaques, Thromb Res, 125, 533, 10.1016/j.thromres.2010.01.049 · DOI
- Calcedo, 2009, Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses, J Infect Dis, 199, 381, 10.1086/595830 · DOI · Paper page
- Lautt, 1987, Conceptual review of the hepatic vascular bed, Hepatology, 7, 952, 10.1002/hep.1840070527 · doi:10.1002/hep.1840070527
- High, 2007, Update on progress and hurdles in novel genetic therapies for hemophilia, Hematology Am Soc Hematol Educ Program, 466, 10.1182/asheducation-2007.1.466 · DOI
- Sands, 2011, AAV-mediated liver-directed gene therapy, Methods Mol Biol, 807, 141, 10.1007/978-1-61779-370-7_6 · DOI · Paper page
- Hurlbut, 2010, Preexisting immunity and low expression in primates highlight translational challenges for liver-directed AAV8-mediated gene therapy, Mol Ther, 18, 1983, 10.1038/mt.2010.175 · DOI · Paper page
- Li, 2012, Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia, Gene Ther, 19, 288, 10.1038/gt.2011.90 · DOI · Paper page
- Chandler, 2011, A barrel of monkeys: scAAV8 gene therapy for hemophilia in nonhuman primates, Mol Ther, 19, 826, 10.1038/mt.2011.73 · DOI
- Gao, 2002, Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy, Proc Natl Acad Sci USA, 99, 11854, 10.1073/pnas.182412299 · DOI · Paper page
- Muir, 1975, Cardiorespiratory effects of rapid saline infusion in normal man, J Appl Physiol, 38, 775, 10.1152/jappl.1975.38.5.786 · doi:10.1152/jappl.1975.38.5.786
- Urata, 1995, Calculation of child and adult standard liver volume for liver transplantation, Hepatology, 21, 1317, 10.1002/hep.1840210515 · DOI · Paper page
- Greenway, 1974, Capacitance effects and blood reservoir function in the splanchnic vascular bed during non-hypotensive haemorrhage and blood volume expansion in anaesthetized cats, J Physiol (Lond), 237, 279, 10.1113/jphysiol.1974.sp010482 · DOI
- Lautt, 1976, Hepatic venous compliance and role of liver as a blood reservoir, Am J Physiol, 231, 292, 10.1152/ajplegacy.1976.231.2.292 · doi:10.1152/ajplegacy.1976.231.2.292
- Mimuro, 2004, Specific detection of human coagulation factor IX in cynomolgus macaques, J Thromb Haemost, 2, 275, 10.1046/j.1538-7933.2003.00572.x · DOI
- Mohammadi, 2004, Expression of the adenovirus E4 34k oncoprotein inhibits repair of double strand breaks in the cellular genome of a 293-based inducible cell line, Nucleic Acids Res, 32, 2652, 10.1093/nar/gkh593 · DOI
Cited by
Immune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955
“72 Limits systemic exposure to the vector.”
Emerging issues in AAV-mediated in vivo gene therapy
Colella, P., Ronzitti, G., & Mingozzi, F. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.007 · Cited by 881
Overcoming Preexisting Humoral Immunity to AAV Using Capsid Decoys
Mingozzi, F., Anguela, X. M., Pavani, G., Chen, Y., Davidson, R. J., Hui, D. J., Yazicioglu, M., Elkouby, L., Hinderer, C. J., Faella, A., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005795 · Cited by 355
“Similarly, use of balloon catheters combined with saline flush has shown some efficacy but only for liver gene transfer in the presence of low to moderate NAb titers (33).”
BackgroundHumoral immune response to AAV
Calcedo, R., & Wilson, J. M. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00341 · Cited by 243
“An approach focused on delivering the vector in the target organ and minimizing the exposure of the vector to circulating NAbs has been shown to be efficient with AAV8 in non-human primate studies targeting the liver via the portal vein (26).”
BackgroundUnraveling the complex story of immune responses to AAV vectors trial after trial.
Vandamme, C., Adjali, O., & Mingozzi, F. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.150 · Cited by 234
Metadata
- Authors
- Mimuro, J., Mizukami, H., Hishikawa, S., Ikemoto, T., Ishiwata, A., Sakata, A., Ohmori, T., Madoiwa, S., Ono, F., Ozawa, K., & Sakata, Y.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2013-02
- Volume
- 21
- Issue
- 2
- Pages
- 318-323
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2039881052
- Cited by
- 74
- References
- 10
- FWCI
- 4.25
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 1344 d)
- Funders
- Ministry of Education, Culture, Sports, Science and Technology
- Ministry of Health, Labour and Welfare
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.